HAHiroyuki Abe

Hiroyuki Abe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroyuki Abe has a total of 277 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Convexal subarachnoid hemorrhage due to infective endocarditis: a rare forensic autopsy case

    by Suguru Torimitsu, Hiroyuki Abe, Shigeki Tsuneya, Yuichiro Hirata, Harutaka Katano, Tadaki Suzuki, Shohei Inui, Keisuke Nyunoya, Go Shirota, Yohsuke Makino

  • Open Access

    Proteomic Signatures Involved in Cardiac Recovery After Mechanical Unloading

    by Yukako Shintani-Domoto, Koji L. Ode, Seitaro Nomura, Yoshiki Nagashima, Osamu Kinoshita, Manami Katoh, Takanobu Yamada, Eisuke Amiya, Kanna Fujita, Hiroyuki Abe, et al.


  • Expression of therapy target molecules in esophagogastric junction and Barrett’s adenocarcinoma

    by Hiroyuki Abe, Masayuki Urabe, Koichi Yagi, Hiroharu Yamashita, Yasuyuki Seto, Tetsuo Ushiku

    Background Recently, novel molecular targeted therapies have been developed for gastric and esophageal adenocarcinomas. We examined the status of therapeutic target molecules in esophagogastric junction (EGJ) and Barrett’s adenocarcinoma. Methods Tissue microarrays were constructed from 114 cases of non-Barrett’s EGJ adenocarcinoma and 30 cases of Barrett’s adenocarcinoma. Immunohistochemistry for mismatch repair proteins, PD-L1, HER2, CLDN18, FGFR2b, and EBER-ISH was performed. When HER2 immunohistochemistry was 2 + , gene amplification was examined using in situ hybridization. Results EBER positivity, mismatch repair deficiency, PD-L1 combined positive score (CPS) ≥ 1, CLDN18 expression ≥ 75%, FGFR2b expression, and HER2 positivity were observed in 7 (6.1%), 11 (9.6%), 70 (61.4%), 38 (33.3%), 6 (5.3%), and 11 (9.6%) cases of EGJ adenocarcinoma as well as in 0 (0%), 0 (0%), 23 (76.7%), 7 (23.3%), 2 (6.7%), and 6 (20.0%) cases of Barrett’s adenocarcinoma, respectively. PD-L1 CPS ≥ 1 cases had longer recurrence-free survival (P = 0.001) and overall survival (P = 0.003) than CPS < 1 cases. Other target molecules were not associated with survival. A total of 93/114 (81.6%) cases of EGJ adenocarcinoma and 26/30 (86.7%) cases of Barrett’s adenocarcinomas expressed at least one target molecule. Conclusions Most EGJ and Barrett’s adenocarcinomas may be eligible for molecular targeted therapy. Appropriate patient stratification based on these molecular tests will be important for precision medicine of the EGJ and Barrett’s adenocarcinoma.


  • PRKAG2 Syndrome Caused by a Novel Missense Variant Mimicked Sporadic Hypertrophic Cardiomyopathy Until Its Progression to Burned-Out Phase

    by Takashi Hiruma, Shunsuke Inoue, Toshiyuki Ko, Seitaro Nomura, Ryo Abe, Chie Bujo, Junichi Ishida, Eisuke Amiya, Masaru Hatano, Hiroyuki Abe, et al.


  • Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7

    by Manami Katoh, Seitaro Nomura, Shintaro Yamada, Masamichi Ito, Hiroki Hayashi, Mikako Katagiri, Tuolisi Heryed, Takayuki Fujiwara, Norifumi Takeda, Miyuki Nishida, et al.

    BACKGROUND: The heart comprises many types of cells such as cardiomyocytes, endothelial cells (ECs), fibroblasts, smooth muscle cells, pericytes, and blood cells. Every cell type responds to various stressors (eg, hemodynamic overload and ischemia) and changes its properties and interrelationships among cells. To date, heart failure research has focused mainly on cardiomyocytes; however, other types of cells and their cell-to-cell interactions might also be important in the pathogenesis of heart failure. METHODS: Pressure overload was imposed on mice by transverse aortic constriction and the vascular structure of the heart was examined using a tissue transparency technique. Functional and molecular analyses including single-cell RNA sequencing were performed on the hearts of wild-type mice and EC-specific gene knockout mice. Metabolites in heart tissue were measured by capillary electrophoresis-time of flight-mass spectrometry system. The vaccine was prepared by conjugating the synthesized epitope peptides with keyhole limpet hemocyanin and administered to mice with aluminum hydroxide as an adjuvant. Tissue samples from heart failure patients were used for single-nucleus RNA sequencing to examine gene expression in ECs and perform pathway analysis in cardiomyocytes. RESULTS: Pressure overload induced the development of intricately entwined blood vessels in murine hearts, leading to the accumulation of replication stress and DNA damage in cardiac ECs. Inhibition of cell proliferation by a cyclin-dependent kinase inhibitor reduced DNA damage in ECs and ameliorated transverse aortic constriction–induced cardiac dysfunction. Single-cell RNA sequencing analysis revealed upregulation of Igfbp7 (insulin-like growth factor-binding protein 7) expression in the senescent ECs and downregulation of insulin signaling and oxidative phosphorylation in cardiomyocytes of murine and human failing hearts. Overexpression of Igfbp7 in the murine heart using AAV9 (adeno-associated virus serotype 9) exacerbated cardiac dysfunction, while EC-specific deletion of Igfbp7 and the vaccine targeting Igfbp7 ameliorated cardiac dysfunction with increased oxidative phosphorylation in cardiomyocytes under pressure overload. CONCLUSIONS: Igfbp7 produced by senescent ECs causes cardiac dysfunction and vaccine therapy targeting Igfbp7 may be useful to prevent the development of heart failure.


  • Open Access

    Changes in SARS-CoV-2 viral load and titers over time in SARS-CoV-2-infected human corpses

    by Sayaka Nagasawa, Yuichiro Hirata, Sho Miyamoto, Seiya Ozono, Shun Iida, Harutaka Katano, Shigeki Tsuneya, Kei Kira, Susumu Kobayashi, Makoto Nakajima, et al.

    High viral titers of infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been detected in human corpses long after death. However, little is known about the kinetics of infectious SARS-CoV-2 in corpses. In this case series study, we investigated the postmortem kinetics of infectious SARS-CoV-2 in human corpses by collecting nasopharyngeal swab samples at multiple time points from six SARS-CoV-2-infected patients after their death. SARS-CoV-2 RNA was detected by quantitative reverse transcription-polymerase chain reaction from nasopharyngeal swab samples collected from all six deceased patients. A viral culture showed the presence of infectious virus in one deceased patient up to 12 days after death. Notably, this patient had a shorter time from symptom onset to death than the other patients, and autopsy samples showed pathological findings consistent with viral replication in the upper respiratory tract. Therefore, this patient died during the viral shedding phase, and the amount of infectious virus in the corpse did not decrease over time up to the date of autopsy (12 days after death). The findings of this study indicate that the persistence of SARS-CoV-2 in corpses can vary among individuals and may be associated with the stage of the disease at the time of death. These important results complement many previously reported findings on the infectivity of SARS-CoV-2 at postmortem.


  • Open Access

    PD‐L1andHLA‐class I expression status and their therapeutic implication in oesophageal small‐cell carcinoma

    by Satoshi Yamashita, Hiroyuki Abe, Hiroharu Yamashita, Koichi Yagi, Yasuyuki Seto, Tetsuo Ushiku

    Aims: Oesophageal small‐cell carcinoma is a rare and highly aggressive subtype of oesophageal cancer with a dismal prognosis. To explore the potential applicability of immunotherapy, we investigated the expression status of programmed death ligand 1 (PD‐L1) and human leukocyte antigen (HLA)‐class I and the degree of tumour‐infiltrating lymphocytes (TILs) in oesophageal small‐cell carcinoma.Methods and results: PD‐L1 and HLA‐class I expression levels were evaluated in 10 pure small‐cell carcinomas and five mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNENs). The combined positive score (CPS) and tumour proportion score (TPS) were used for PD‐L1 assessment. Immunohistochemistry for mismatch repair (MMR) proteins was also performed. PD‐L1 immunohistochemistry demonstrated CPS ≥1 in nine (60%), CPS ≥10 in five (33%), and TPS ≥1 in five (33%) cases. Overall survival was significantly longer in patients with CPS ≥1 than in those with CPS 50% tumour cells) was noted in five cases (33%), with no significant correlation with PD‐L1 expression status. Among the five MiNENs, HLA‐class I expression was decreased in the small‐cell carcinoma component of three cases. HLA‐class I deficiency was significantly associated with higher TNM stage and reduced TIL levels. MMR deficiency was not observed in any case.Conclusion: Given that a significant subset (40%) exhibited PD‐L1 CPS ≥1 with preserved HLA‐class I expression and high levels of TIL, the PD‐1/PD‐L1 pathway is a potential therapeutic target for oesophageal small‐cell carcinoma.


  • Lost expression of AT‐rich interaction domain 1A in the gastric mucosa—A constituent of field cancerization in the stomach

    by Hiroyuki Abe, Hirofumi Rokutan, Yasushi Totoki, Hiromi Nakamura, Tatsuhiro Shibata, Tetsuo Ushiku, Masashi Fukayama

    Abnormalities of the AT‐rich interaction domain 1A (ARID1A) occur in cancer tissues and precursors or premalignant lesions in various organs. To investigate the significance of ARID1A abnormalities in the early phase of cancer development in the stomach, we screened for ARID1A loss and p53 overexpression in glands in non‐neoplastic gastric mucosa using immunohistochemistry. We tested 230 tissue blocks of 77 patients with gastric carcinoma, and in 10% of non‐neoplastic mucosa we detected ARID1A‐lost and in 3.7% p53‐overexpressed foci. Loss of ARID1A expression occurred in the scales of several glands, which were morphologically characterized as authentic, pseudo‐pyloric, or intestinal metaplastic glands devoid of dysplastic changes. In contrast, p53‐overexpressed foci were detected in dysplastic intestinal metaplasia. In early gastric cancer cases (n = 46), ARID1A‐lost foci were frequent in samples of patients with Epstein–Barr virus‐associated gastric carcinoma (p = 0.037). Ultra‐deep DNA sequencing of ARID1A‐lost foci revealed frameshift and nonsense mutations in ARID1A. Mapping abnormal glands in the entire resected stomach of the three selected patients demonstrated that ARID1A‐lost foci clustered with p53 abnormal glands. ARID1A‐lost epithelial cells may develop clonal growth through the pathway, different from p53‐abnormal intestinal metaplasia, and require one or more events to develop into an overt carcinoma, such as EBV infection.


  • Top Cited Papers

    Multiancestry genomic and transcriptomic analysis of gastric cancer

    by Yasushi Totoki, Mihoko Saito-Adachi, Yuichi Shiraishi, Daisuke Komura, Hiromi Nakamura, Akihiro Suzuki, Kenji Tatsuno, Hirofumi Rokutan, Natsuko Hama, Shogo Yamamoto, et al.

    Gastric cancer is among the most common malignancies worldwide, characterized by geographical, epidemiological and histological heterogeneity. Here, we report an extensive, multiancestral landscape of driver events in gastric cancer, involving 1,335 cases. Seventy-seven significantly mutated genes (SMGs) were identified, including ARHGAP5 and TRIM49C. We also identified subtype-specific drivers, including PIGR and SOX9, which were enriched in the diffuse subtype of the disease. SMGs also varied according to Epstein–Barr virus infection status and ancestry. Non-protein-truncating CDH1 mutations, which are characterized by in-frame splicing alterations, targeted localized extracellular domains and uniquely occurred in sporadic diffuse-type cases. In patients with gastric cancer with East Asian ancestry, our data suggested a link between alcohol consumption or metabolism and the development of RHOA mutations. Moreover, mutations with potential roles in immune evasion were identified. Overall, these data provide comprehensive insights into the molecular landscape of gastric cancer across various subtypes and ancestries.


  • Open Access

    High titers of infectious SARS-CoV-2 in corpses of patients with COVID-19

    by Hisako Saitoh, Yuko Sakai-Tagawa, Sayaka Nagasawa, Suguru Torimitsu, Kazumi Kubota, Yuichiro Hirata, Kiyoko Iwatsuki-Horimoto, Ayumi Motomura, Namiko Ishii, Keisuke Okaba, et al.